Apr. 1 at 1:06 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics (
$CVKD) – Cadrenal Reports FY2025 With Clinical Progress
Progress On CAD-1005 Reported With FY2025 Results. Cadrenal reported a loss for 4Q25 of
$3.0 million or $(1.42) per share and a FY2025 loss of
$13.2 million or $(6.64) per share. Importantly, it recently held its End-Of-Phase 2 meeting with the FDA to receive guidance for the planned Phase 3 trial for CAD-1005 in HIT (heparin-induced thrombocytopenia).
Read full report here: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-cadrenal-reports-fy2025-with-clinical-progress
